Browse PVR

Summary
SymbolPVR
Namepoliovirus receptor
Aliases CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform Alpha: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform Delta: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform Beta: Secreted.; SUBCELLULAR LOCATION: Isoform Gamma: Secreted.
Domain PF08205 CD80-like C2-set immunoglobulin domain
PF07686 Immunoglobulin V-set domain
Function

Mediates NK cell adhesion and triggers NK cell effector functions. Binds two different NK cell receptors: CD96 and CD226. These interactions accumulates at the cell-cell contact site, leading to the formation of a mature immunological synapse between NK cell and target cell. This may trigger adhesion and secretion of lytic granules and IFN-gamma and activate cytoxicity of activated NK cells. May also promote NK cell-target cell modular exchange, and PVR transfer to the NK cell. This transfer is more important in some tumor cells expressing a lot of PVR, and may trigger fratricide NK cell activation, providing tumors with a mechanism of immunoevasion. Plays a role in mediating tumor cell invasion and migration. ; FUNCTION: (Microbial infection) Acts as a receptor for poliovirus. May play a role in axonal transport of poliovirus, by targeting virion-PVR-containing endocytic vesicles to the microtubular network through interaction with DYNLT1. This interaction would drive the virus-containing vesicle to the axonal retrograde transport. ; FUNCTION: (Microbial infection) Acts as a receptor for Pseudorabies virus. ; FUNCTION: (Microbial infection) Is prevented to reach cell surface upon infection by Human cytomegalovirus /HHV-5, presumably to escape immune recognition of infected cell by NK cells.

> Gene Ontology
 
Biological Process GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001912 positive regulation of leukocyte mediated cytotoxicity
GO:0001913 T cell mediated cytotoxicity
GO:0001914 regulation of T cell mediated cytotoxicity
GO:0001916 positive regulation of T cell mediated cytotoxicity
GO:0002228 natural killer cell mediated immunity
GO:0002250 adaptive immune response
GO:0002347 response to tumor cell
GO:0002418 immune response to tumor cell
GO:0002420 natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0002423 natural killer cell mediated immune response to tumor cell
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002709 regulation of T cell mediated immunity
GO:0002711 positive regulation of T cell mediated immunity
GO:0002715 regulation of natural killer cell mediated immunity
GO:0002717 positive regulation of natural killer cell mediated immunity
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002831 regulation of response to biotic stimulus
GO:0002833 positive regulation of response to biotic stimulus
GO:0002834 regulation of response to tumor cell
GO:0002836 positive regulation of response to tumor cell
GO:0002837 regulation of immune response to tumor cell
GO:0002839 positive regulation of immune response to tumor cell
GO:0002855 regulation of natural killer cell mediated immune response to tumor cell
GO:0002857 positive regulation of natural killer cell mediated immune response to tumor cell
GO:0002858 regulation of natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0002860 positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules
GO:0008037 cell recognition
GO:0019058 viral life cycle
GO:0030260 entry into host cell
GO:0031341 regulation of cell killing
GO:0031343 positive regulation of cell killing
GO:0031349 positive regulation of defense response
GO:0034330 cell junction organization
GO:0034332 adherens junction organization
GO:0042267 natural killer cell mediated cytotoxicity
GO:0042269 regulation of natural killer cell mediated cytotoxicity
GO:0042271 susceptibility to natural killer cell mediated cytotoxicity
GO:0044409 entry into host
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045216 cell-cell junction organization
GO:0045954 positive regulation of natural killer cell mediated cytotoxicity
GO:0046718 viral entry into host cell
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0060370 susceptibility to T cell mediated cytotoxicity
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
Molecular Function GO:0001618 virus receptor activity
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0005913 cell-cell adherens junction
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-418990: Adherens junctions interactions
R-HSA-446728: Cell junction organization
R-HSA-1500931: Cell-Cell communication
R-HSA-421270: Cell-cell junction organization
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-420597: Nectin/Necl trans heterodimerization
Summary
SymbolPVR
Namepoliovirus receptor
Aliases CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PVR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PVR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25893601Plasma Cell MyelomaPromote immunity (T cell function)In this study using this unique mouse model of multiple myeloma (MM), we demonstrate the importance of NK and CD8+ T cells in MM immunosurveillance and response to treatment in vivo through CD226 and CD155 interactions.
19801517Ovarian CarcinomaPromote immunityCoincubation of NK cells with ovarian carcinoma cells expressing the DNAM-1 ligand CD155 led to reduction of DNAM-1 expression. Therefore, NK cell-mediated rejection of ovarian carcinoma may be limited by perturbed DNAM-1 expression on tumor-associated NK cells induced by chronic ligand exposure.
29308322MelanomaPromote immunity (NK cell function)We demonstrate that BRAFV600E mutant melanoma cells cultured in the presence of vemurafenib, strongly decreased surface expression of ligands for NK activating receptors including the NKG2D-ligand, MICA, and the DNAM-1 ligand, CD155, and became significantly less susceptible to NK cell attack.
29757192Melanoma; Colon Adenocarcinoma; FibrosarcomaInhibit immunity (T cell function); Resistant to immunotherapyCD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. Cd155-/- mice displayed reduced tumor growth and metastasis via DNAM-1 upregulation and enhanced effector function of CD8+ T and NK cells, respectively. CD155-deleted tumor cells also displayed slower tumor growth and reduced metastases, demonstrating the importance of a tumor-intrinsic role of CD155. CD155 absence on host and tumor cells exerted an even greater inhibition of tumor growth and metastasis. Blockade of PD-1 or both PD-1 and CTLA4 was more effective in settings in which CD155 was limiting, suggesting the clinical potential of cotargeting PD-L1 and CD155 function.
25209846Hepatocellular CarcinomaPromote immunity(NK cell function)Here, we demonstrated that activated unfolded protein response (UPR) attenuated the sensitivity of human hepatocellular carcinoma cell (HCC) to NK-cell cytotoxicity by decreasing the expression level of CD226 ligand CD155 in HCC
23349395Hepatocellular CarcinomaPromote immunityHere, we show that DNA damage response–induced expression of the DNAM-1 ligand CD155 in tumor cells leads to spontaneous rejection of tumor cells from the blood of young Em-myc mice
Summary
SymbolPVR
Namepoliovirus receptor
Aliases CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PVR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPVR
Namepoliovirus receptor
Aliases CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PVR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1310.692
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1730.912
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.350.775
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4290.252
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6760.689
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.120.957
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1490.73
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.340.821
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0710.965
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2860.838
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8450.669
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0110.917
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PVR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPVR
Namepoliovirus receptor
Aliases CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PVR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPVR
Namepoliovirus receptor
Aliases CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PVR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PVR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPVR
Namepoliovirus receptor
Aliases CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PVR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPVR
Namepoliovirus receptor
Aliases CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PVR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPVR
Namepoliovirus receptor
Aliases CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PVR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPVR
Namepoliovirus receptor
Aliases CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PVR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PVR.
ID Name Drug Type Targets #Targets
DB03203SphingosineSmall MoleculeGLTP, PVR2
DB08231Myristic acidSmall MoleculeABL1, ARF1, ARF6, ECI2, FKBP1A, GM2A, GUCA1A, HNF4A, INS, LY96, NC ......20